Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 21 |
| List of Tables | 19 | 3 |
| List of Figures | 22 | 1 |
| Introduction | 23 | 1 |
| Global Markets Direct Report Coverage | 23 | 1 |
| Diffuse Large B-Cell Lymphoma Overview | 24 | 1 |
| Therapeutics Development | 25 | 2 |
| Pipeline Products for Diffuse Large B-Cell Lymphoma Overview | 25 | 1 |
| Pipeline Products for Diffuse Large B-Cell Lymphoma Comparative Analysis | 26 | 1 |
| Diffuse Large B-Cell Lymphoma Therapeutics under Development by Companies | 27 | 6 |
| Diffuse Large B-Cell Lymphoma Therapeutics under Investigation by Universities/Institutes | 33 | 1 |
| Diffuse Large B-Cell Lymphoma Pipeline Products Glance | 34 | 3 |
| Late Stage Products | 34 | 1 |
| Clinical Stage Products | 35 | 1 |
| Early Stage Products | 36 | 1 |
| Diffuse Large B-Cell Lymphoma Products under Development by Companies | 37 | 10 |
| Diffuse Large B-Cell Lymphoma Products under Investigation by Universities/Institutes | 47 | 1 |
| Diffuse Large B-Cell Lymphoma Companies Involved in Therapeutics Development | 48 | 78 |
| 3SBio Inc. | 48 | 1 |
| AbbVie Inc | 49 | 1 |
| Acetylon Pharmaceuticals, Inc. | 50 | 1 |
| Affimed GmbH | 51 | 1 |
| Amgen Inc. | 52 | 1 |
| Arrien Pharmaceuticals, LLC | 53 | 1 |
| Arvinas, Inc. | 54 | 1 |
| Asana BioSciences, LLC | 55 | 1 |
| AstraZeneca Plc | 56 | 1 |
| Aurigene Discovery Technologies Limited | 57 | 1 |
| Bayer AG | 58 | 1 |
| BeiGene, Ltd. | 59 | 1 |
| Biocon Limited | 60 | 1 |
| BioNTech AG | 61 | 1 |
| Boehringer Ingelheim GmbH | 62 | 1 |
| Bristol-Myers Squibb Company | 63 | 1 |
| Celgene Corporation | 64 | 1 |
| Cell Medica Limited | 65 | 1 |
| Cell>Point, L.L.C. | 66 | 1 |
| Cellular Biomedicine Group, Inc. | 67 | 1 |
| Clevexel Pharma SA | 68 | 1 |
| Constellation Pharmaceuticals, Inc. | 69 | 1 |
| CSPC Pharmaceutical Group Limited | 70 | 1 |
| CTI BioPharma Corp. | 71 | 1 |
| Curis, Inc. | 72 | 1 |
| Cyclacel Pharmaceuticals, Inc. | 73 | 1 |
| eFFECTOR Therapeutics, Inc. | 74 | 1 |
| Eisai Co., Ltd. | 75 | 1 |
| EpiZyme, Inc. | 76 | 1 |
| Erytech Pharma SA | 77 | 1 |
| Evotec AG | 78 | 1 |
| F. Hoffmann-La Roche Ltd. | 79 | 1 |
| Genentech, Inc. | 80 | 1 |
| Genosco | 81 | 1 |
| Gilead Sciences, Inc. | 82 | 1 |
| GlaxoSmithKline Plc | 83 | 1 |
| H3 Biomedicine Inc. | 84 | 1 |
| Hutchison MediPharma Limited | 85 | 1 |
| ImmunoGen, Inc. | 86 | 1 |
| Immunomedics, Inc. | 87 | 1 |
| Immunovaccine, Inc. | 88 | 1 |
| Incyte Corporation | 89 | 1 |
| Inflection Biosciences Limited | 90 | 1 |
| Innovent Biologics, Inc. | 91 | 1 |
| Johnson &Johnson | 92 | 1 |
| Juno Therapeutics Inc. | 93 | 1 |
| Karyopharm Therapeutics, Inc. | 94 | 1 |
| Kite Pharma Inc | 95 | 1 |
| Mabion SA | 96 | 1 |
| mAbxience S.A. | 97 | 1 |
| MedImmune LLC | 98 | 1 |
| Medivation, Inc. | 99 | 1 |
| Merck &Co., Inc. | 100 | 1 |
| Merck KGaA | 101 | 1 |
| Millennium Pharmaceuticals Inc | 102 | 1 |
| Mirati Therapeutics Inc. | 103 | 1 |
| Molplex Ltd. | 104 | 1 |
| MorphoSys AG | 105 | 1 |
| Neumedicines Inc. | 106 | 1 |
| Nimbus Therapeutics, LLC | 107 | 1 |
| Nordic Nanovector ASA | 108 | 1 |
| Novartis AG | 109 | 1 |
| Ono Pharmaceutical Co., Ltd. | 110 | 1 |
| Pfizer Inc. | 111 | 1 |
| Philogen S.p.A. | 112 | 1 |
| Portola Pharmaceuticals, Inc. | 113 | 1 |
| RedHill Biopharma Ltd. | 114 | 1 |
| Respiratorius AB | 115 | 1 |
| Rhizen Pharmaceuticals S.A. | 116 | 1 |
| Sandoz International GmbH | 117 | 1 |
| Seattle Genetics, Inc. | 118 | 1 |
| Selvita S.A. | 119 | 1 |
| Shanghai Henlius Biotech Co., Ltd. | 120 | 1 |
| Sigma-Tau S.p.A. | 121 | 1 |
| Taiho Pharmaceutical Co., Ltd. | 122 | 1 |
| Takeda Pharmaceutical Company Limited | 123 | 1 |
| TG Therapeutics, Inc. | 124 | 1 |
| TRACON Pharmaceuticals Inc | 125 | 1 |
| Diffuse Large B-Cell Lymphoma Therapeutics Assessment | 126 | 16 |
| Assessment by Monotherapy Products | 126 | 1 |
| Assessment by Combination Products | 127 | 1 |
| Assessment by Target | 128 | 5 |
| Assessment by Mechanism of Action | 133 | 5 |
| Assessment by Route of Administration | 138 | 2 |
| Assessment by Molecule Type | 140 | 2 |
| Drug Profiles | 142 | 550 |
| 187Re-EC-G Drug Profile | 142 | 1 |
| ABC-294640 Drug Profile | 143 | 6 |
| acalabrutinib Drug Profile | 149 | 3 |
| ACY-775 Drug Profile | 152 | 1 |
| AFM-11 Drug Profile | 153 | 1 |
| AFM-13 Drug Profile | 154 | 3 |
| alisertib Drug Profile | 157 | 5 |
| ARN-3261 Drug Profile | 162 | 1 |
| ARV-771 Drug Profile | 163 | 1 |
| ASN-002 Drug Profile | 164 | 1 |
| asparaginase Drug Profile | 165 | 6 |
| atezolizumab Drug Profile | 171 | 12 |
| azacitidine Drug Profile | 183 | 5 |
| AZD-3965 Drug Profile | 188 | 1 |
| AZD-9150 Drug Profile | 189 | 2 |
| baltaleucel-T Drug Profile | 191 | 2 |
| BAY-1143572 Drug Profile | 193 | 1 |
| Betalutin Drug Profile | 194 | 5 |
| BGB-3111 Drug Profile | 199 | 2 |
| BI-836826 Drug Profile | 201 | 1 |
| birabresib Drug Profile | 202 | 2 |
| blinatumomab Drug Profile | 204 | 9 |
| BLyS-gel Drug Profile | 213 | 1 |
| BMS-986016 Drug Profile | 214 | 1 |
| bortezomib Drug Profile | 215 | 8 |
| brentuximab vedotin Drug Profile | 223 | 24 |
| BTM-10XX Drug Profile | 247 | 1 |
| buparlisib hydrochloride Drug Profile | 248 | 5 |
| BVX-20 Drug Profile | 253 | 1 |
| CA-4948 Drug Profile | 254 | 2 |
| carfilzomib Drug Profile | 256 | 12 |
| CBM-C19.1 Drug Profile | 268 | 1 |
| CBM-C20.1 Drug Profile | 269 | 2 |
| CC-122 Drug Profile | 271 | 2 |
| CC-223 Drug Profile | 273 | 1 |
| CC-90011 Drug Profile | 274 | 1 |
| Cellular Immunotherapy for Oncology Drug Profile | 275 | 1 |
| Cellular Immunotherapy to Target CD19 for Acute Lymphocytic Leukemia and Diffuse Large B-Cell Lymphoma Drug Profile | 276 | 1 |
| Cellular Immunotherapy to Target CD19 for B-Cell Leukemias and B-Cell Lymphomas Drug Profile | 277 | 1 |
| Cellular Immunotherapy to Target CD19 for Oncology Drug Profile | 278 | 1 |
| Cellular Immunotherapy to Target CD19 for Oncology Drug Profile | 279 | 1 |
| Cellular Immunotherapy to Target CD20 for B-Cell Leukemia and Lymphoma Drug Profile | 280 | 1 |
| Cellular Immunotherapy to Target CD30 for Oncology Drug Profile | 281 | 1 |
| cerdulatinib Drug Profile | 282 | 3 |
| ChiLob-7/4 Drug Profile | 285 | 2 |
| copanlisib hydrochloride Drug Profile | 287 | 4 |
| CPI-0610 Drug Profile | 291 | 2 |
| CPI-169 Drug Profile | 293 | 1 |
| CUDC-907 Drug Profile | 294 | 4 |
| CVXL-0074 Drug Profile | 298 | 1 |
| CYC-065 Drug Profile | 299 | 3 |
| daratumumab Drug Profile | 302 | 12 |
| Darleukin Drug Profile | 314 | 2 |
| denintuzumab mafodotin Drug Profile | 316 | 3 |
| DPX-Survivac Drug Profile | 319 | 8 |
| DTRMWXHS-12 Drug Profile | 327 | 1 |
| durvalumab Drug Profile | 328 | 11 |
| E-7449 Drug Profile | 339 | 1 |
| eFT-508 Drug Profile | 340 | 2 |
| entospletinib Drug Profile | 342 | 2 |
| epacadostat Drug Profile | 344 | 5 |
| everolimus Drug Profile | 349 | 11 |
| GS-5829 Drug Profile | 360 | 1 |
| GSK-2816126 Drug Profile | 361 | 1 |
| HMPL-523 Drug Profile | 362 | 2 |
| huCART19 Drug Profile | 364 | 1 |
| IBL-301 Drug Profile | 365 | 1 |
| ibrutinib Drug Profile | 366 | 23 |
| idasanutlin Drug Profile | 389 | 2 |
| IGN-002 Drug Profile | 391 | 2 |
| IMGN-529 Drug Profile | 393 | 2 |
| inebilizumab Drug Profile | 395 | 2 |
| inotuzumab ozogamicin Drug Profile | 397 | 4 |
| IT-901 Drug Profile | 401 | 1 |
| ixazomib citrate Drug Profile | 402 | 10 |
| JCAR-014 Drug Profile | 412 | 3 |
| JCAR-015 Drug Profile | 415 | 5 |
| JCAR-017 Drug Profile | 420 | 3 |
| JNJ-64052781 Drug Profile | 423 | 2 |
| KPT-8602 Drug Profile | 425 | 2 |
| KTEC-19 Drug Profile | 427 | 8 |
| LAM-002A Drug Profile | 435 | 1 |
| lenalidomide Drug Profile | 436 | 14 |
| M-7583 Drug Profile | 450 | 1 |
| MAK-683 Drug Profile | 451 | 1 |
| mitoxantrone hydrochloride Drug Profile | 452 | 2 |
| mocetinostat Drug Profile | 454 | 4 |
| Monoclonal Antibody Conjugate to Target CD22 for Hematological Cancers Drug Profile | 458 | 1 |
| MOR-208 Drug Profile | 459 | 5 |
| ND-2110 Drug Profile | 464 | 1 |
| ND-2158 Drug Profile | 465 | 1 |
| nivolumab Drug Profile | 466 | 33 |
| NMIL-121 Drug Profile | 499 | 3 |
| obinutuzumab Drug Profile | 502 | 7 |
| ONC-201 Drug Profile | 509 | 5 |
| ONO-4059 Drug Profile | 514 | 2 |
| PCAR-019 Drug Profile | 516 | 1 |
| PCAR-119 Drug Profile | 517 | 1 |
| pecazine Drug Profile | 518 | 1 |
| pembrolizumab Drug Profile | 519 | 35 |
| pidilizumab Drug Profile | 554 | 3 |
| pixantrone dimaleate Drug Profile | 557 | 7 |
| polatuzumab vedotin Drug Profile | 564 | 2 |
| Pt-EC-G Drug Profile | 566 | 1 |
| rituximab biosimilar Drug Profile | 567 | 2 |
| rituximab biosimilar Drug Profile | 569 | 1 |
| rituximab biosimilar Drug Profile | 570 | 1 |
| rituximab biosimilar Drug Profile | 571 | 1 |
| rituximab biosimilar Drug Profile | 572 | 2 |
| rituximab biosimilar Drug Profile | 574 | 1 |
| rituximab biosimilar Drug Profile | 575 | 1 |
| rituximab biosimilar Drug Profile | 576 | 1 |
| rituximab biosimilar Drug Profile | 577 | 1 |
| romidepsin Drug Profile | 578 | 3 |
| RP-6530 Drug Profile | 581 | 2 |
| ruxolitinib phosphate Drug Profile | 583 | 13 |
| sapanisertib Drug Profile | 596 | 3 |
| SCT-400 Drug Profile | 599 | 1 |
| SEA-CD40 Drug Profile | 600 | 1 |
| SEL-24B489 Drug Profile | 601 | 1 |
| selinexor Drug Profile | 602 | 18 |
| SGN-CD70A Drug Profile | 620 | 1 |
| SGNCD-19B Drug Profile | 621 | 1 |
| SH-7129 Drug Profile | 622 | 1 |
| Small Molecule for Diffuse Large B-Cell Lymphoma Drug Profile | 623 | 1 |
| Small Molecule for Diffuse Large B-Cell Lymphoma and Non-Small Cell Lung Cancer Drug Profile | 624 | 1 |
| Small Molecule to Inhibit SYK for Diffuse Large B-Cell Lymphoma and Peripheral T-Cell Lymphoma Drug Profile | 625 | 1 |
| Small Molecules for Diffuse Large B Cell Lymphoma Drug Profile | 626 | 1 |
| Small Molecules to Inhibit BCL6 for Diffuse Large B-Cell Lymphoma Drug Profile | 627 | 1 |
| Small Molecules to Inhibit IRAK4 for Immunology and Oncology Drug Profile | 628 | 1 |
| sotrastaurin acetate Drug Profile | 629 | 2 |
| spebrutinib besylate Drug Profile | 631 | 2 |
| ST-7612AA1 Drug Profile | 633 | 1 |
| Synthetic Peptide to Inhibit Bcl-6 for Diffuse Large B-Cell Lymphoma and Acute Lymphoblastic Leukemia Drug Profile | 634 | 1 |
| Synthetic Peptides to Target RBCK1 for Diffuse Large B-cell Lymphoma Drug Profile | 635 | 1 |
| TAK-659 Drug Profile | 636 | 1 |
| TAS-5567 Drug Profile | 637 | 1 |
| tazemetostat Drug Profile | 638 | 7 |
| TGR-1202 Drug Profile | 645 | 7 |
| TGR-1202 + ublituximab Drug Profile | 652 | 5 |
| tisagenlecleucel-T Drug Profile | 657 | 5 |
| TRC-102 Drug Profile | 662 | 2 |
| ulocuplumab Drug Profile | 664 | 2 |
| urelumab Drug Profile | 666 | 2 |
| utomilumab Drug Profile | 668 | 2 |
| valproate sodium Drug Profile | 670 | 1 |